1. Variation in US acute ischemic stroke treatment by hospital regions: limited endovascular access despite evidence.
- Author
-
Stein LK, Maillie L, Erdman J, Loebel E, Mayman N, Sharma A, Wolmer S, Tuhrim S, Fifi JT, Jette N, Mocco J, and Dhamoon MS
- Subjects
- Aged, Humans, United States epidemiology, Retrospective Studies, Cross-Sectional Studies, Treatment Outcome, Medicare, Hospitals, Ischemic Stroke, Brain Ischemia diagnosis, Brain Ischemia therapy, Stroke diagnosis, Stroke surgery
- Abstract
Background: Although national organizations recognize the importance of regionalized acute ischemic stroke (AIS) care, data informing expansion are sparse. We assessed real-world regional variation in emergent AIS treatment, including growth in revascularization therapies and stroke center certification. We hypothesized that we would observe overall growth in revascularization therapy utilization, but observed differences would vary greatly regionally., Methods: A retrospective cross-sectional analysis was carried out of de-identified national inpatient Medicare Fee-for-Service datasets from 2016 to 2019. We identified AIS admissions and treatment with thrombolysis and endovascular thrombectomy (ET) with International Classification of Diseases, 10th Revision, Clinical Modification codes. We grouped hospitals in Dartmouth Atlas of Healthcare Hospital Referral Regions (HRR) and calculated hospital, demographic, and acute stroke treatment characteristics for each HRR. We calculated the percent of hospitals with stroke certification and AIS cases treated with thrombolysis or ET per HRR., Results: There were 957 958 AIS admissions. Relative mean (SD) growth in percent of AIS admissions receiving revascularization therapy per HRR from 2016 to 2019 was 13.4 (31.7)% (IQR -6.1-31.7%) for thrombolysis and 28.0 (72.0)% (IQR 0-56.0%) for ET. The proportion of HRRs with decreased or no difference in ET utilization was 38.9% and the proportion of HRRs with decreased or no difference in thrombolysis utilization was 32.7%. Mean (SD) stroke center certification proportion across HRRs was 45.3 (31.5)% and this varied widely (IQR 18.3-73.4%)., Conclusions: Overall growth in AIS treatment has been modest and, within HRRs, growth in AIS treatment and the proportion of centers with stroke certification varies dramatically., Competing Interests: Competing interests: NJ receives grant funding paid to her institution for grants unrelated to this work from NINDS (NIH U24NS107201, NIH IU54NS100064, 3R01CA202911-05S1, R21NS122389, R01HL161847). She receives an honorarium for her work as an Associate Editor of Epilepsia. JM is an investor in: Cerebrotech, Imperative Care, Endostream, Viseon, BlinkCNS, Serenity, NTI, RIST, NRT, Viz.ai, Synchron, Tulavi, Sim&Cure, Songbird, Borvo, Whisper, Neurolutions. He serves, or has recently served, as a consultant for: Imperative Care, Cerebrotech, Endostream, Vastrax, RIST, Synchron, NRT, Viz.ai, Perflow, CVAid., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF